---
document_datetime: 2026-02-10 13:43:23
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vueway-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vueway-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.356909
conversion_datetime: 2026-02-13 18:27:33.378379
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vueway

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary     |
|----------------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-------------|
| PSUR / EMA/PSUR/0000296586 |         |                                     |                                             |                                  | Maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000249008   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of new population (0 to 2 years of age patients) for Elucirem / Vueway, based on final results from study GDX-44-015; this is a phase ii clinical study concerning gadopiclenol pharmacokinetics, safety and efficacy in pediatric patients < 2 years of age undergoing contrast-enhanced MRI; extension of indication is also supported with the non-clinical data. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 0.4 of the   | 11/12/2025   | 22/01/2026   | SmPC and PL   | Please refer to Scientific Discussion 'Elucirem/Vueway - II- EMAVR0000289008'   |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000253566   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2 Changes in the manufacturing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 04/09/2025   |              |               |                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                          | process of the active substance - B.I.a.2.b Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product - Accepted                                                                                                                                                                      |            |            |                 |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| Variation type IA_IN / EMA/VR/0000302726 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                 | 17/10/2025 | 22/01/2026 | Annex II and PL |
| Variation type IB / EMA/VR/0000308193    | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                                                                                                                                                                      | 17/11/2025 |            |                 |
| Variation type IB / EMA/VR/0000276336    | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the | 26/06/2025 |            |                 |

<div style=\"page-break-after: always\"></div>

| finished product - B.II.b.3.z Change in the holding time of an intermediate - Accepted   |
|------------------------------------------------------------------------------------------|